You are here: Home » PTI Stories » National » News
Business Standard

Shilpa Medicare launches cancer drug at monthly therapy cost of Rs 6,440

Health Medical Pharma

Press Trust of India  |  New Delhi 

Shilpa Medicare on Friday said it has launched its generic version of cancer drug Dasatinib at a monthly therapy cost of Rs 6,440.

The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 12, 2020. The current monthly therapy cost of innovator is approximately Rs 1.65 lakh, Shilpa Medicare said in a regulatory filing.

Shilpa Medicare has launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name Dasashil, it added.

The branded generic anti-cancer drug will be available in all dosage strengths of 20/ 50/ 70/ 100 mg tablets. It is used for treatment of Chronic Myeloid Leukaemia (CML), the company said.

"Dasashil will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability," Shilpa Medicare claimed.

The products are being manufactured and supplied from the company's US Food and Drug Administration-approved manufacturing facility, it added.

"Today there are around 10,000 to 15,000 new patients of CML in India, which can be benefited by Dasashil tablets," the company.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, April 24 2020. 10:44 IST